Qiagen's high P/E ratio is worrisome due to its poor earnings forecast. Despite the high P/E, investors retain their shares, but this earnings growth rate may eventually impact the share price. The high P/E and future earnings predictions pose a substantial risk to shareholders and potential investors.
Qiagen's performance is strong due to strategic profit reinvestment, leading to significant earnings growth. Its respectable ROE contributes to a net income increase. Yet, forecasts anticipate a slowdown in future earnings growth.
快而精医药股票讨论区
2023Q1营收下滑22.8%,营业利润大幅下滑52%,净利润下滑45.3%,这已经是连续第四个季度营收和利润下滑。
目前市盈率24.9,市盈率TTM已经上升到29.7,暂时缺乏吸引力。
暂无评论